Area of Interest Genomics Analysis PCR Applications Pathogen Detection with Microfluidics

SARS-CoV-2 Mutation Assay Panel 

Developing Bimodal Single-Cell Omics - Ansuman Satpathy, MD, PhDReflex-free detection of Variants of Concern 

SARS-CoV-2, like all RNA viruses, evolves and mutates. Since its discovery, the viral sequence for the novel coronavirus has accumulated a staggering number of mutations, giving rise to more virulent, transmissible and deadly variations that are taking hold across the globe. Since the virus can evolve, the assays designed to detect it must evolve as well. 

Blue icon illustrating pathogen detection application

The Fluidigm RT-PCR based Advanta® SARS-CoV-2 Mutation Assay Panel is an expansion of the Advanta pathogen detection portfolio and can concurrently detect the reference virus and mutations associated with six Variants of Concern identified by the CDC and WHO. Leveraging our proprietary microfluidics technology along with the Biomark™ HD platform and an IFC controller, the detection of these new mutations is performed seamlessly without the need for additional integrated fluidic circuits (IFCs), run reagents or sample volume, providing more data without additional labor. As the virus continues to evolve, the assay’s open design enables this solution to evolve along with it. 

Product Highlights 

  • Reflex-free workflow: Detects SARS-CoV-2 and key mutations concurrently from the same input sample on one IFC, saving reagents, samples and time 

  • Saliva-based and extraction-free: Performs equivalently to comparator nasal tests utilizing convenient and noninvasive sample collection without the need for commercial extraction kits 

  • More valuable data: Supports detection and surveillance of key mutations from a single high-throughput workflow that supports up to 6,000 samples per day 

  • Flexible: Enables convenient addition of mutations emerging in the future, unlike other multiplex RT-PCR assays, due to the open architecture of the IFC 

Panel Layout

N1 

N2 

RNase P 

N1 

N2 

RNase P 

N1 

N2 

RNase P 

N1 

N2 

RNase P 

L452R mutant 

K417N mutant 

N501Y mutant 

L452R wild type 

K417N wild type 

N501Y wild type 

∆69/70 mutant 

K417T mutant 

E484K mutant 

∆69/70 wild type 

K417T wild type 

E484K wild type 

The Mutation Assay expands on our current pathogen detection portfolio by concurrently detecting SARS-CoV-2 N1 and N2 genes and probe pairs to independently target both the wild type and mutation of each allele of the virus. 

 

Mutation 
(first reported) 

B.1.1.7 
(UK) 

B.1.351 
(S. Africa) 

P.1 
(Brazil) 

B.1.427 
B.1.429 
(US-CA) 

B.1.526 
(US-NY) 

B.1.617.2 
(India) 

WHO Identification 

Alpha 

Beta 

Gamma 

Epsilon 

Iota 

Delta 

K417N 

 

 

 

 

  

K417T 

 

 

 

 

  

L452R 

 

 

 

 

E484K 

 

 

  

N501Y 

 

 

  

∆69/70 

 

 

 

 

  

The mutations chosen for this panel align with current CDC and WHO Variants of Concern. 

Covid lowlabor workflow infograph

Advanta SARS-CoV-2 Mutation Assay Panel workflow total instrument run time <3 hours

 

 

 

New tech note for Delta and Delta+ variants using Advanta SARS-CoV-2 Mutation Assay Panel 

DOWNLOAD TECH NOTE

Advanta SARS mytation assay panel flyer thumbnail

 

 

 

COVID-19, cardiovascular disease and mass cytometry - Hema Kothari, PhDExtending global understanding of COVID-19 - Dr. Dexi Chen, PhD, MD Detect mutations associated with Variants of Concern. 

DOWNLOAD FLYER

Learn more about the assay.

Download quick reference

Download full protocol

publications

Powering over 1,500 scientific publications with our products

VIEW ALL

Dr. Dexi Chen, PhD, MD

Spotlight IMC DR. DEXI CHEN

Achieving multi-omic insights with microfluidics and CyTOF technology

Dr. Luc Teyton, MD, PhD

Spotlight MC DR. LUC TEYTON

How one lab explores the immune system one T cell at a time

Scott Magness, PhD

Spotlight MF SCOTT MAGNESS

Investigating transcriptomic changes at the microscale level

Simone Mayer, PhD

Spotlight MF Simone Mayer

Simone Mayer, PhD, explains how using multimodal analysis helped reveal new insights

Jo Vandesompele, PhD

Spotlight MF Jo Vandesompele

Jo Vandesompele at Ghent University discusses a deep dive into single-cell sequencing

Christophe Lancrin, PhD

Spotlight MF Christophe Lancrin

Christophe Lancrin on revealing new transcription factors using C1 and Biomark

customer stories

Learn more about how our customers are leveraging Fluidigm technology

VIEW ALL

Unless explicitly and expressly stated otherwise, all Fluidigm products are provided for Research Use Only, not for use in diagnostic procedures. For more information see www.fluidigm.com/legal/notices